Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study - Markman, M; Blessing, J; Rubin, S C (Gynecol Oncol, 2006)